ERBB2 and breast carcinoma: To investigate gene-delivered enzyme prodrug therapy (GDEPT) to treat HER2+ breast cancer, researchers used a retrovirus to deliver prodrug-activating protein encoded plasmids into MSCs, which then secreted EVs with prodrug-encoding mRNA for GDEPT therapy 117.